SAM
PRTK

Stansberry Asset Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Stansberry Asset Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-73,808
Closed -$753K – 106
2018
Q2 		$753K Sell
73,808
-1,531
-2% -$17.3K 0.25% 61
2018
Q1 		$979K Buy
75,339
+3,537
+5% +$52.7K 0.48% 46
2017
Q4 		$1.28M Buy
+71,802
New +$1.5M 0.55% 54

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Stansberry Asset Management's PRTK Position: Q3 2018 in Review

Stansberry Asset Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2018, closing a stake of 73,808 shares — an estimated $753K sold.

Stansberry Asset Management first reported a position in PRTK in Q4 2017 and held it in 3 quarters. The position peaked at $1.28M in Q4 2017. 105 funds tracked by Wall St. Rank hold PRTK as of Q3 2018.

  • Stansberry Asset Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Stansberry Asset Management sold 73,808 Paratek Pharmaceuticals, Inc. shares in Q3 2018, an estimated $753K.
  • Stansberry Asset Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2017 and held it in 3 quarters.
  • Stansberry Asset Management's Paratek Pharmaceuticals, Inc. position peaked at $1.28M in Q4 2017.
  • 105 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2018.

Based on Stansberry Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.